BD (Becton, Dickinson and Company) (NYSE: BDX), a leading global medical technology company, today announced results for its first quarter of fiscal 2023, which ended December 31, 2022.

Merck (NYSE: MRK), known as MSD outside the United States and Canada, today announced financial results for the fourth quarter and full year of 2022.

Thermo Fisher Scientific Inc., the world leader in serving science, today reported its financial results for the fourth quarter and full year ended December 31, 2022.

SQI Diagnostics Inc., a leader in the science of lung health that develops and manufactures respiratory health and precision medicine tests today reported its financial and operational results for the fourth quarter and fiscal year ended September 30, 2022.

On the evening of January 19, Andon Health Co., Ltd. released the 2022 performance forecast, and it is expected that the company's net profit in 2022 will be 16.5 billion CNY to 17.5 billion CNY, a year-on-year increase of 1715.9% to 1825.95%.

On January 18, Shanghai Kehua Bio-Engineering Co., Ltd. released the 2022 annual fiscal forecast.

GE HealthCare, a leader in precision care innovation, today announced preliminary unaudited revenue results for the fourth quarter and full year 2022. The Company also issued Organic revenue growth, Adjusted EBIT margin, and Free cash flow conversion guidance for 2023.

THERADIAG, a company specializing in in vitro diagnostics of autoimmune diseases and Theranostics, today reported its 2022 annual revenue and its cash position at December 31, 2022.

New Horizon Health announced earnings forecast for financial year 2022: total revenue expected to be RMB 766 million, up 260% year-on-year; Bioeasy 2022 expected net profit CNY 110 million to CNY 150 million

According to CAIVD statistics, at present, the main in vitro diagnostic listed enterprises total: 62. They cover three segments: production, service and distribution. Among them, 46 are production enterprises, 11 are service enterprises and 5 are distribution enterprises.